SLC5A2 and Glycosuria: While both agents have been associated with enhanced fatty acid oxidation, the underlying mechanisms appear to differ: imeglimin improves mitochondrial function and thereby facilitates more efficient fatty acid oxidation at the cellular level [12], whereas SGLT2 inhibitors induce a systemic substrate shift from glucose toward fatty acid and ketone body utilization through glucosuria-induced energy loss [29].